Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the
All the children in the study testing a medicine called crofelemer for a rare disease moved into the next phase of testing. When all patients keep going in a study, it usually means the medicine is working well enough to keep studying.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.